Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 1.00 |
| ▸ | DDB1 | Q16531 | 16/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.61 |
| ▸ | TNF | P01375 | 1/20 | 0.61 |
| ▸ | IL1B | P01584 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | STAT3 | P40763 | 2/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14085581 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL24377001 | 0.91 | CRBN (0.84) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL29622415 | 0.91 | CRBN (0.84) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL30850501 | 0.91 | CRBN (0.83) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL24621043 | 0.91 | CRBN (0.83) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL18379320 | 0.91 | CRBN (0.83) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL17884453 | 0.91 | CRBN (0.83) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL18379436 | 0.91 | CRBN (0.83) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL19481530 | 0.91 | DDB1 (0.83) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL30850474 | 0.90 | CRBN (0.82) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145315-A1 | TARGETED PROTEIN DEGRADERS OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) | NORTHWESTERN UNIVERSITY (US) | 2024-07-04 | — | — | WO | claimed |
| WO-2023215321-A2 | POLYNUCLEOTIDE COMPOSITIONS FOR THE TREATMENT OF PREMATURE TERMINATION DISEASES | CONFLUENCE THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | WO | claimed |
| US-20230312639-A1 | GPER PROTEOLYTIC TARGETING CHIMERAS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2023-10-05 | — | — | US | claimed |
| EP-4138921-A1 | GPER PROTEOLYTIC TARGETING CHIMERAS | University Of Iowa Research Foundation (US) | 2023-03-01 | — | — | EP | claimed |
| US-20220023431-A1 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) PROTEIN | NORTHWESTERN UNIVERSITY | 2022-01-27 | — | — | US | claimed |
| US-20260131010-A1 | MENIN PROTEOLYSIS TARGETING CHIMERAS (PROTACS) | UNIV TEXAS (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260053934-A1 | DUAL ACTION ONLY PROTEOLYSIS TARGETING CHIMERAS AND USES THEREOF | UNIV MASSACHUSETTS (US) | 2026-02-26 | — | — | US | disclosed |
| US-12492209-B2 | Substituted [1,2,4]triazolo[4,3-c]pyrimidines that induce degradation of embryonic ectoderm development (EED) protein | NORTHWESTERN UNIVERSITY (US) | 2025-12-09 | — | — | US | disclosed |
| US-12491252-B2 | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 | NORTHWESTERN UNIVERSITY (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12311029-B2 | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein | NORTHWESTERN UNIVERSITY (US) | 2025-05-27 | — | — | US | disclosed |
| CN-119732914-A | Nanometer degradation agent based on proteolytic targeting chimeric molecule, preparation method and application thereof | 中国科学院长春应用化学研究所 | 2025-04-01 | — | — | CN | disclosed |
| US-11890346-B2 | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC protein | NORTHWESTERN UNIVERSITY (US) | 2024-02-06 | — | — | US | disclosed |
| WO-2023215321-A2 | POLYNUCLEOTIDE COMPOSITIONS FOR THE TREATMENT OF PREMATURE TERMINATION DISEASES | CONFLUENCE THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230346953-A1 | SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2 | UNITED STATES GOVERNMENT | 2023-11-02 | — | — | US | disclosed |
| US-20230312639-A1 | GPER PROTEOLYTIC TARGETING CHIMERAS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2023-10-05 | — | — | US | disclosed |
| WO-2023074780-A1 | THERAPEUTIC AGENT COMPOSITION | 国立大学法人愛媛大学 | 2023-05-04 | — | — | WO | disclosed |
| EP-4138921-A1 | GPER PROTEOLYTIC TARGETING CHIMERAS | University Of Iowa Research Foundation (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2022185319-A1 | UBIQUITIN LIGASE KPC1-PEPTIDE BASED PROTEOLYSIS TARGETING CHIMERAS (PROTAC) AND USES THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2022-09-09 | — | — | WO | disclosed |
| US-20220023431-A1 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) PROTEIN | NORTHWESTERN UNIVERSITY | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12311029-B2 | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein | IDO1, IDO2, KMO | CRBN 95/4885DDB1 1376/4885IKZF3 151/4885 |
| US-20230312639-A1 | GPER PROTEOLYTIC TARGETING CHIMERAS | GPER1, ESR1, ADRM1 | CRBN 658/4885DDB1 1582/4885IKZF3 1524/4885 |
| US-20260131010-A1 | MENIN PROTEOLYSIS TARGETING CHIMERAS (PROTACS) | CRBN, UBE3C, PSME3 | CRBN 1/4885DDB1 757/4885IKZF3 744/4885 |
| US-12492209-B2 | Substituted [1,2,4]triazolo[4,3-c]pyrimidines that induce degradation of embryonic ectoderm development (EED) protein | EED, CUL3, PSME3 | CRBN 73/4885DDB1 923/4885IKZF3 433/4885 |
| US-20230346953-A1 | SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2 | EZH2, BAZ2A, BAZ2B | CRBN 33/4885DDB1 613/4885IKZF3 91/4885 |
| US-20260053934-A1 | DUAL ACTION ONLY PROTEOLYSIS TARGETING CHIMERAS AND USES THEREOF | PSMA1, PSMB1, PSME1 | CRBN 77/4885DDB1 1611/4885IKZF3 503/4885 |
| US-20220023431-A1 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) PROTEIN | IDO1, IDO2, KMO | CRBN 176/4885DDB1 1197/4885IKZF3 151/4885 |
| US-12491252-B2 | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 | EZH2, BAZ2A, BAZ2B | CRBN 33/4885DDB1 613/4885IKZF3 91/4885 |
| US-11890346-B2 | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC protein | MYCBP, MYC, MYCBP2 | CRBN 6/4885DDB1 743/4885IKZF3 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.